A defined antigen skin test for the diagnosis of bovine tuberculosis

Authors Organisations
  • Sreenidhi Srinivasan(Author)
    The Pennsylvania State University
    Animal and Plant Health Agency
  • Gareth Jones(Author)
    Animal and Plant Health Agency
  • Maroudam Veerasami(Author)
    The Pennsylvania State University
    Cisgen Biotech Discoveries
  • Sabine Steinbach(Author)
    Animal and Plant Health Agency
  • Thomas Holder(Author)
    Animal and Plant Health Agency
  • Aboma Zewude(Author)
    Addis Ababa University
  • Abebe Fromsa(Author)
    Addis Ababa University
  • Gobena Ameni(Author)
    Addis Ababa University
  • Laurel Easterling(Author)
    The Pennsylvania State University
  • Douwe Bakker(Author)
    The Pennsylvania State University
  • Nicholas Jeuleff(Author)
    Bill & Melinda Gates Foundation
  • Glen Gifford(Author)
    World Organization for Animal Health
  • Glyn Hewinson(Author)
  • Hans-Martin Vordermeier(Author)
  • Vivek Kapur(Author)
    The Pennsylvania State University
Type Article
Original languageEnglish
Article numbereaax4899
JournalScience Advances
Issue number7
Publication statusPublished - 17 Jul 2019
Permanent link
Show download statistics
View graph of relations
Citation formats


Bovine tuberculosis (bTB) is a major zoonotic disease of cattle that is endemic in much of the world, limiting livestock productivity and representing a global public health threat. Because the standard tuberculin skin test precludes implementation of Bacille Calmette-Guérin (BCG) vaccine–based control programs, we here developed and evaluated a novel peptide-based defined antigen skin test (DST) to diagnose bTB and to differentiate infected from vaccinated animals (DIVA). The results, in laboratory assays and in experimentally or naturally infected animals, demonstrate that the peptide-based DST provides DIVA capability and equal or superior performance over the extant standard tuberculin surveillance test. Together with the ease of chemical synthesis, quality control, and lower burden for regulatory approval compared with recombinant antigens, the results of our studies show that the DST considerably improves a century-old standard and enables the development and implementation of critically needed surveillance and vaccination programs to accelerate bTB control.